{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:56:18Z","timestamp":1794491778673,"version":"4.9.1"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R\/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg\/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg\/m2; day 1 and cytarabine 2x2g\/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC\/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC\/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC\/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3\/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1\/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1\/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R\/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.<\/jats:p>","DOI":"10.3324\/haematol.2019.243238","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T16:10:59Z","timestamp":1586448659000},"page":"1129-1137","source":"Crossref","is-referenced-by-count":91,"title":["Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study"],"prefix":"10.3324","volume":"106","author":[{"family":"Marie Jos\u00e9 Kersten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Julia Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jos\u00e9e M. Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wouter J. Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Franck Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pieternella J. Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pauline Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Martin Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Thomas Gastinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Roberto Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Coreline N. Burggraaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marcel Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sanne H. Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anne I.J. Arens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Roelf Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Harm van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marta Lopez-Yurda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Arjan Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Daphne De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anton Hagenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"24271","doi-asserted-by":"crossref","unstructured":"Schmitz N, Pfistner B, Sextro M. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-2071.","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"24272","doi-asserted-by":"crossref","unstructured":"Linch DC, Winfield D, Goldstone AH. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-1054.","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"24273","doi-asserted-by":"crossref","unstructured":"Majhail NS, Weisdorf DJ, Defor TE. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006; 12(10):1065-1072.","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"24274","doi-asserted-by":"crossref","unstructured":"Josting A, Rudolph C, Mapara M. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005; 16(1):116-123.","DOI":"10.1093\/annonc\/mdi003"},{"key":"24275","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97(3):616-623.","DOI":"10.1182\/blood.V97.3.616"},{"key":"24276","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012; 119(7):1665-1670.","DOI":"10.1182\/blood-2011-10-388058"},{"key":"24277","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010; 148(6):890-897.","DOI":"10.1111\/j.1365-2141.2009.08037.x"},{"key":"24278","doi-asserted-by":"crossref","unstructured":"Devillier R, Coso D, Castagna L. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica. 2012; 97(7):1073-1079.","DOI":"10.3324\/haematol.2011.056051"},{"key":"24279","doi-asserted-by":"crossref","unstructured":"Smeltzer JP, Cashen AF, Zhang Q. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(11):1646-1652.","DOI":"10.1016\/j.bbmt.2011.04.011"},{"key":"24280","doi-asserted-by":"crossref","unstructured":"Santoro A, Magagnoli M, Spina F. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007; 92(1):35-41.","DOI":"10.3324\/haematol.10661"},{"key":"24281","doi-asserted-by":"crossref","unstructured":"Labrador J, Cabrero-Calvo M, Perez-Lopez E. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014; 93(10):1745-1753.","DOI":"10.1007\/s00277-014-2114-0"},{"key":"24282","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Aleman BMP, Andre M. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv19-iv29.","DOI":"10.1093\/annonc\/mdy080"},{"key":"24283","doi-asserted-by":"crossref","unstructured":"Younes A, Bartlett NL, Leonard JP. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-1821.","DOI":"10.1056\/NEJMoa1002965"},{"key":"24284","doi-asserted-by":"crossref","unstructured":"Falini B, Pileri S, Pizzolo G. CD30 (Ki- 1) molecule, a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995; 85(1):1-14.","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511"},{"key":"24285","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Schr\u00f6der H, Yahalom J. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015; 16(3):284-292.","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"24286","doi-asserted-by":"crossref","unstructured":"LaCasce AS, Bociek RG, Sawas A. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018; 132(1):40-48.","DOI":"10.1182\/blood-2017-11-815183"},{"key":"24287","doi-asserted-by":"crossref","unstructured":"Chen R, Palmer JM, Martin P. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodkgin lymphoma. Biol Blood Marrow Transplant. 2015; 21(12):2136-2140.","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"24288","doi-asserted-by":"crossref","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019; 30(4):612-620.","DOI":"10.1093\/annonc\/mdz009"},{"key":"24289","doi-asserted-by":"crossref","unstructured":"Broccoli A, Argnani L, Botto B. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019; 9(12):100.","DOI":"10.1038\/s41408-019-0265-x"},{"key":"24290","doi-asserted-by":"crossref","unstructured":"Herrera AF, Palmer J, Martin P. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018; 29(3):724-730.","DOI":"10.1093\/annonc\/mdx791"},{"key":"24291","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18):2183-2189.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"24292","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Mooij H, Zijlstra J. Phase 1 dose-escalation study of brentuximabvedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: the Transplant BRaVE study. Haematologica. 2018; 104(4):e151-e153.","DOI":"10.3324\/haematol.2018.196899"},{"key":"24293","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"24294","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"24295","doi-asserted-by":"crossref","unstructured":"Natkunam Y, Gratzinger D, Chadburn A. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. Blood. 2018; 132(18):1871-1878.","DOI":"10.1182\/blood-2018-04-842559"},{"key":"24296","doi-asserted-by":"crossref","unstructured":"Josting A, Muller H, Borchmann P. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010; 28(34):5074-5080.","DOI":"10.1200\/JCO.2010.30.5771"},{"key":"24297","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Schoder H, Gavane S. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017; 130(20):2196-2203.","DOI":"10.1182\/blood-2017-06-788877"},{"key":"24298","doi-asserted-by":"crossref","unstructured":"Sureda A, Constans M, Iriondo A. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16(4):625-633.","DOI":"10.1093\/annonc\/mdi119"},{"key":"24299","doi-asserted-by":"crossref","unstructured":"Hahn T, McCarthy PL, Carreras J. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013; 19(12):1740-1744.","DOI":"10.1016\/j.bbmt.2013.09.018"},{"key":"24300","doi-asserted-by":"crossref","unstructured":"Santoro A, Mazza R, Pulsoni A. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016; 34(27):3293-3299.","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"24301","doi-asserted-by":"crossref","unstructured":"Arai S, Fanale M, DeVos S. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013; 54(11):2531-2533.","DOI":"10.3109\/10428194.2013.798868"},{"key":"24302","doi-asserted-by":"crossref","unstructured":"Sorigue M, Sancho JM, Pineda A. Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leuk Res. 2017; 58:98-101.","DOI":"10.1016\/j.leukres.2017.05.001"},{"key":"24303","doi-asserted-by":"crossref","unstructured":"McKeage M. Comparative adverse effect profiles of platinum drugs. Drug Safety. 1995; 13(4):228-244.","DOI":"10.2165\/00002018-199513040-00003"},{"key":"24304","doi-asserted-by":"crossref","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman T. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018; 131(11):1183-1194.","DOI":"10.1182\/blood-2017-10-811224"},{"key":"24305","doi-asserted-by":"crossref","unstructured":"Coppell JA, Richardson PG, Soiffer R. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16(2):157-168.","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"24306","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Nademanee A, Masszi T. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385(9980):1853-1862.","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"24307","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Copie-Bergman C, Damotte D. Gray-zone lymphoma between cHL and large B-cell lymphoma. A histopathologic series from the LYSA. Am J Surg Pathol. 2019; 43(3):341-351.","DOI":"10.1097\/PAS.0000000000001198"},{"key":"24308","doi-asserted-by":"crossref","unstructured":"Pilichowska M, Pittaluga S, Ferry JA. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances. 2017; 1(26):2600-2609.","DOI":"10.1182\/bloodadvances.2017009472"},{"key":"24309","doi-asserted-by":"crossref","unstructured":"Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/ dendritic cell neoplasms. Expert Rev Hematol. 2017; 10(3):239-249.","DOI":"10.1080\/17474086.2017.1281122"},{"key":"24310","doi-asserted-by":"crossref","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"24311","doi-asserted-by":"crossref","unstructured":"Mettler J, Muller H, Voltin CA. Metabolic tumour volume for response prediction in advance-stage Hodgkin lymphoma. J Nucl Med. 2019; 60(2):207-211.","DOI":"10.2967\/jnumed.118.210047"},{"key":"24312","doi-asserted-by":"crossref","unstructured":"El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY. FDG-PET\/CT in the management of lymphomas: current status and future directions. J Intern Med. 2018; 284(4):358-376.","DOI":"10.1111\/joim.12813"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9712\/70757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9712\/70758","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9712\/70757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:43Z","timestamp":1794045403000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.243238","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}